我武生物(300357) - 2018 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders reached ¥85,398,504.94, a growth of 22.42% year-on-year[9] - Operating revenue for the period was ¥166,984,187.12, reflecting a 29.96% increase compared to the same period last year[9] - The net profit excluding non-recurring gains and losses was ¥83,249,054.80, a 23.42% increase year-on-year[9] - The company reported a basic earnings per share of ¥0.2936, reflecting a 22.44% increase compared to the same period last year[9] - The net profit for the current period was ¥87,560,739.67, representing a growth of 22.8% from ¥71,274,098.17 in the same period last year[44] - The company reported a total profit of ¥226,352,867.92 for the current period, which is an increase from ¥177,907,450.19 in the previous period, marking a growth of around 27.2%[52] Assets and Liabilities - Total assets increased to ¥1,001,923,973.03, up 18.11% from the previous year[9] - Total liabilities rose to ¥48,944,314.65 from ¥47,252,091.52, a slight increase of about 4%[36] - The company's equity attributable to shareholders increased to ¥931,898,069.95 from ¥803,361,735.71, reflecting a growth of approximately 16%[37] - The total assets amounted to ¥1,001,923,973.03, compared to ¥848,311,200.92 at the beginning of the year[32] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥132,382,655.68, up 12.08%[9] - The net increase in cash and cash equivalents was ¥302,295,108.83, up 510.07% year-on-year, mainly due to the increase in net cash flow from investing activities[21] - The cash flow from operating activities generated a net amount of ¥132,382,655.68, up from ¥118,117,953.32 in the previous period, reflecting an increase of approximately 12.5%[53] - The company's total cash flow from financing activities resulted in a net outflow of -¥64,640,000.00, compared to -¥40,400,000.00 in the previous period, reflecting a larger outflow[55] Investments and Expenses - Research and development expenses for the quarter were ¥3,253,633.11, up from ¥1,956,363.57, showing an increase of approximately 66%[38] - Research and development expenses rose to ¥3,214,875.61, up 64.2% from ¥1,956,363.57 in the previous period, indicating a strong focus on innovation[43] - The company recorded investment income of ¥6,589,202.67, up from ¥5,407,162.92, which is an increase of approximately 21.8%[51] - The company reported an investment income of ¥1,365,391.58, down from ¥2,441,884.21, reflecting a decrease of 44%[44] Shareholder Equity and Dividends - The company's share capital increased by ¥129,280,000.00, an 80.00% rise due to the capital reserve conversion plan[18] - The company paid out 64,640,000.00 CNY in dividends and interest, which is an increase from 40,400,000.00 CNY in the previous period, reflecting a rise of 60%[59] Market and Growth Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[49] - Operating revenue increased by ¥92,071,310.57, a growth of 31.36% year-on-year, mainly driven by the rising sales volume of the company's main products as the desensitization treatment market expands[20] Miscellaneous - There were no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[25][26] - The third quarter report was not audited, which may affect the reliability of the financial data presented[60]